vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Mama's Creations, Inc. (MAMA). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $47.3M, roughly 1.8× Mama's Creations, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs 1.1%, a 5.7% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 50.0%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $3.7M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Mama's Creations, Inc. is a U.S.-based food manufacturing enterprise that produces a wide portfolio of refrigerated ready-to-eat and heat-and-serve food products, including Italian-style meatballs, sausages, pasta dishes, and other prepared meals. It mainly distributes its offerings to grocery retailers, mass merchandisers and foodservice partners across the United States, focusing on convenient, high-quality comfort food for daily consumer demand.
BLLN vs MAMA — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $47.3M |
| Net Profit | $5.7M | $540.0K |
| Gross Margin | 69.9% | 23.6% |
| Operating Margin | 11.5% | 1.7% |
| Net Margin | 6.8% | 1.1% |
| Revenue YoY | 117.4% | 50.0% |
| Net Profit YoY | 138.3% | 31.7% |
| EPS (diluted) | $0.10 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $47.3M | ||
| Q3 25 | $83.5M | $35.2M | ||
| Q2 25 | — | $35.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $31.5M | ||
| Q3 24 | $38.4M | $28.4M | ||
| Q2 24 | — | $29.8M | ||
| Q1 24 | — | $26.7M |
| Q4 25 | — | $540.0K | ||
| Q3 25 | $5.7M | $1.3M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.6M | ||
| Q4 24 | — | $410.0K | ||
| Q3 24 | $-14.9M | $1.1M | ||
| Q2 24 | — | $553.0K | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | 23.6% | ||
| Q3 25 | 69.9% | 24.9% | ||
| Q2 25 | — | 26.1% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | 52.6% | 24.2% | ||
| Q2 24 | — | 25.0% | ||
| Q1 24 | — | 29.3% |
| Q4 25 | — | 1.7% | ||
| Q3 25 | 11.5% | 4.8% | ||
| Q2 25 | — | 4.5% | ||
| Q1 25 | — | 5.7% | ||
| Q4 24 | — | 1.8% | ||
| Q3 24 | -32.9% | 5.7% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 7.4% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | 6.8% | 3.6% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | -38.8% | 4.0% | ||
| Q2 24 | — | 1.9% | ||
| Q1 24 | — | 5.3% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | $0.10 | $0.03 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | $-1.47 | $0.03 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $18.1M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $49.6M |
| Total Assets | $327.5M | $84.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.1M | ||
| Q3 25 | $195.2M | $9.4M | ||
| Q2 25 | — | $12.0M | ||
| Q1 25 | — | $7.2M | ||
| Q4 24 | — | $9.3M | ||
| Q3 24 | — | $7.4M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $11.0M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $49.6M | ||
| Q3 25 | $-239.5M | $29.6M | ||
| Q2 25 | — | $26.4M | ||
| Q1 25 | — | $24.9M | ||
| Q4 24 | — | $23.0M | ||
| Q3 24 | $-242.9M | $22.3M | ||
| Q2 24 | — | $20.3M | ||
| Q1 24 | — | $19.6M |
| Q4 25 | — | $84.0M | ||
| Q3 25 | $327.5M | $51.2M | ||
| Q2 25 | — | $52.7M | ||
| Q1 25 | — | $47.1M | ||
| Q4 24 | — | $47.9M | ||
| Q3 24 | — | $43.0M | ||
| Q2 24 | — | $47.2M | ||
| Q1 24 | — | $45.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $3.9M |
| Free Cash FlowOCF − Capex | $6.5M | $3.7M |
| FCF MarginFCF / Revenue | 7.7% | 7.8% |
| Capex IntensityCapex / Revenue | 8.8% | 0.4% |
| Cash ConversionOCF / Net Profit | 2.42× | 7.16× |
| TTM Free Cash FlowTrailing 4 quarters | — | $6.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.9M | ||
| Q3 25 | $13.8M | $-1.7M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $-857.0K | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $6.7M |
| Q4 25 | — | $3.7M | ||
| Q3 25 | $6.5M | $-2.2M | ||
| Q2 25 | — | $5.5M | ||
| Q1 25 | — | $-930.0K | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | — | $-4.0M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | — | 7.8% | ||
| Q3 25 | 7.7% | -6.2% | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | -2.8% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | -14.1% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | — | 24.8% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | 8.8% | 1.5% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 7.2% | ||
| Q3 24 | — | 5.6% | ||
| Q2 24 | — | 3.8% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | 7.16× | ||
| Q3 25 | 2.42× | -1.31× | ||
| Q2 25 | — | 4.85× | ||
| Q1 25 | — | -0.54× | ||
| Q4 24 | — | 11.71× | ||
| Q3 24 | — | -2.10× | ||
| Q2 24 | — | 6.58× | ||
| Q1 24 | — | 4.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
MAMA
Segment breakdown not available.
